Singapore, Sept. 5 -- Biocytogen Pharmaceuticals(Beijing), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, andMerck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP).

Under the terms of the agreement, Biocytogen will provide proprietary, fully human antibodies derived from its RenMice(R)platform for evaluation in Merck KGaA, Darmstadt, Germany's antibody-conjugated LNP services. Merck KGaA, Darmstadt, Germany has been granted a...